{
    "nct_id": "NCT05850234",
    "official_title": "A Phase 1b/2 Study of GC012F (AZD0120), a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects With Relapsed/Refractory Multiple Myeloma",
    "inclusion_criteria": "* Males and females ≥18 years of age at the time of consent\n* Written informed consent in accordance with federal, local, and institutional guidelines\n* Have an ECOG performance status of 0 or 1\n* Documented diagnosis of MM per IMWG diagnostic criteria\n* Received at least three prior MM treatment lines of therapy\n* Have received as part of their previous therapy a PI and IMiD and an antiCD38 antibody.\n* Have documented evidence of progressive disease by the IMWG criteria.\n* Subjects must have measurable disease at screening, as defined by any of the following: serum monoclonal paraprotein (M-protein) ≥1.0g/dL (10 g/L); urine M-protein ≥200 mg/24 h; serum FLC assay: involved FLC level is ≥10 mg/dL (100 mg/L) and serum kappa lambda FLC ratio is abnormal.\n* Adequate bone marrow and organ function assessment at screening according to the hematological, hepatic, and renal parameters listed in the CSP\n\nExclusion Criteria :\n\n* Diagnosed or treated for invasive malignancy other than multiple myeloma, except: Malignancy treated with curative intent and with no known active disease present for ≥2 years before enrollment; or\n* Adequately treated non-melanoma skin cancer without evidence of disease.\n* The following cardiac conditions:\n* New York Heart Association (NYHA) stage III or IV congestive heart failure\n* Myocardial infarction or coronary artery bypass graft (CABG) ≤6 months prior to enrollment\n* History of clinically significant ventricular arrhythmia or unexplained syncope, not believed to be vasovagal in nature or due to dehydration\n* History of severe non-ischemic cardiomyopathy\n* Received either of the following:\n* An allogenic stem cell transplant within 6 months before apheresis. Subjects who received an allogeneic transplant must be off all immunosuppressive medications for 6 weeks without signs of graft-versus-host disease (GVHD).\n* An autologous stem cell transplant ≤12 weeks before apheresis\n* Known active, or prior history of central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of multiple myeloma.\n* Plasma cell leukemia at the time of screening (>2.0×109 /L plasma cells by standard differential), Waldenström's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or primary AL amyloidosis.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}